| Targeting the endocannabinoid system: to enhance or reduce? | 2008/05/01 | English | 587 |
| Animal Models of sepsis: setting the stage | 2005/10/01 | English | 585 |
| Kinase inhibitors: the road ahead | 2018/03/16 | English | 582 |
| The productivity crisis in pharmaceutical R&D | 2011/06/01 | English | 577 |
| Trends in the exploitation of novel drug targets | 2011/08/01 | English | 576 |
| Is there new hope for therapeutic matrix metalloproteinase inhibition? | 2014/11/07 | English | 573 |
| Therapeutic strategies for rheumatoid arthritis | 2003/06/01 | English | 572 |
| The emerging field of nanotube biotechnology | 2003/01/01 | English | 571 |
| Resolution of inflammation: a new therapeutic frontier | 2016/03/29 | English | 570 |
| The biology and therapeutic targeting of the proprotein convertases | 2012/04/20 | English | 566 |
| Emerging concepts in the science of vaccine adjuvants | 2021/04/06 | English | 566 |
| Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles | 2017/05/19 | English | 566 |
| The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery | 2010/12/01 | English | 563 |
| Targeting the Hedgehog pathway in cancer | 2006/12/01 | English | 563 |
| Endogenous kynurenines as targets for drug discovery and development | 2002/08/01 | English | 562 |
| More than one reason to rethink the use of peptides in vaccine design | 2007/05/01 | English | 560 |
| From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors | 2017/02/17 | English | 555 |
| The IL-33/ST2 pathway: therapeutic target and novel biomarker | 2008/10/01 | English | 554 |
| Targeting the translation machinery in cancer | 2015/03/06 | English | 553 |
| Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases | 2007/05/01 | English | 553 |
| Signalling bias in new drug discovery: detection, quantification and therapeutic impact | 2012/02/15 | English | 551 |
| Protein aggregation diseases: pathogenicity and therapeutic perspectives | 2010/03/01 | English | 550 |
| SGLT2 inhibition — a novel strategy for diabetes treatment | 2010/05/28 | English | 549 |
| Inflammatory bone loss: pathogenesis and therapeutic intervention | 2012/03/01 | English | 549 |
| Advances in targeting cyclic nucleotide phosphodiesterases | 2014/04/01 | English | 547 |
| Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors | 2003/07/01 | English | 545 |
| Inflammatory Resolution: new opportunities for drug discovery | 2004/05/01 | English | 545 |
| Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases | 2007/06/01 | English | 544 |
| Voltage-gated potassium channels as therapeutic targets | 2009/12/01 | English | 540 |
| Integration of virtual and high-throughput screening | 2002/11/01 | English | 537 |